Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CollaGenex Pharmaceuticals to Present at the Deutsche Bank Securities Health Care Conference on May 7, 2002.


Business Editors, Health & Medical Writers

NEWTOWN, Pa.--(BUSINESS WIRE)--April 29, 2002

CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI CGPI Corporate Goods Price Index (Japan)
CGPI Capital Goods Price Index (New Zealand) 
) announced today that the Company's Chairman, Chief Executive Officer and President, Brian M. Gallagher, Ph.D. will present at the Deutsche Bank Securities, Inc. Health Care Conference.

The presentation is scheduled for 1:30 PM on Tuesday May 7, 2002 at the Marriott Baltimore Waterfront Hotel in Baltimore, Maryland.

The presentation will be available as a live audio webcast at www.db.com/conferences. A replay of the presentation will be available by the end of the day, and will be archived online for 90 days.

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company currently focused on providing innovative medical therapies to the dental and dermatology markets.

Currently, the Company's 120-person professional dental pharmaceutical sales force markets Periostat(R), the first and only pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues, Vioxx(R), a Merck & Co. drug that CollaGenex co-promotes for the treatment of acute dental pain, and Atridox(R), Atrisorb(R) and Atrisorb-D(R), Atrix Laboratories Inc.'s products for the treatment of adult periodontitis periodontitis

Inflammation of soft tissues around the teeth (see tooth). Poor dental hygiene leads to deposition of bacterial plaque on the teeth below the gum line, irritating and eroding nearby tissues.
.

Research has shown that the enzyme suppression technology underlying Periostat may also be applicable to other diseases involving inflammation and/or destruction of the body's connective tissues, including acne, rosacea Rosacea Definition

Rosacea is a skin disease typically appearing in people during their 30s and 40s. It is marked by redness (erythema) of the face, flushing of the skin, and the presence of hard pimples (papules) or pus-filled pimples (pustules), and
, blepharitis blepharitis /bleph·a·ri·tis/ (blef?ah-ri´tis) inflammation of the eyelids.

blepharitis angula´ris  inflammation involving the angles of the eyelids.
 and cancer metastases Metastasis (plural, metastases)
A tumor growth or deposit that has spread via lymph or blood to an area of the body remote from the primary tumor.

Mentioned in: Malignant Melanoma
, among others.

CollaGenex is further developing Periostat as well as a series of novel, proprietary compounds known as IMPACS IMPACS Institute for Media, Policy and Civil Society
IMPACS Integrated Manufacturing Planning and Control System
IMPACS International Message and Packet Switching Service
 (Inhibitors of Multiple Proteases and Cytokines Cytokines
Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors.
) to address these applications.

To receive additional information on the Company, please visit our Web site at www.collagenex.com.

Periostat(R), Metastat(R) and IMPACS(R) are trademarks of CollaGenex Pharmaceuticals, Inc.

VIOXX(R)is a trademark of Merck & Co., Inc.

Atridox, Atrisorb and Atrisorb-D are trademarks of Atrix Laboratories, Inc.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 29, 2002
Words:300
Previous Article:Contact Sports Signs Alexander ``Sasha'' Volkov; Contact Sports Sponsors Ukranian National Team; Contact Sports Sponsors NEBL's B.C. Kiev Team.
Next Article:Kidney Transplant Patient in BioTransplant and Massachusetts General Hospital Study Nears Four Year Milestone Without Immune Suppressive Drugs.
Topics:



Related Articles
CollaGenex Pharmaceuticals, Inc. Signs Distributor Agreement for Periostat for Israel.
CollaGenex Pharmaceuticals Announces Signing of Export Marketing Agreement for Middle East.
CollaGenex Announces Presentation at Tucker Anthony Sutro Health Care Conference.
CollaGenex Pharmaceuticals' Presentation at Deutsche Banc Alex. Brown Conference to be Webcast Live.
CollaGenex Pharmaceuticals, Inc. to Present at UBS Warburg Global Specialty Pharmaceuticals Conference.
CollaGenex Licenses Novel Dermal Drug Delivery Platform.
CollaGenex Pharmaceuticals Announces Launch Of Atrisorb-D; Unique GTR Barrier Membrane Incorporates Doxycycline to Reduce Bacterial Growth.
CollaGenex Pharmaceuticals, Inc. to Present at the SG Cowen 22nd Annual Health Care Conference on March 14, 2002.
CollaGenex Pharmaceuticals Announces First Quarter 2002 Earnings Conference Call.
CollaGenex Pharmaceuticals to Present at the UBS Warburg Global Specialty Pharmaceuticals Conference on June 6, 2002.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles